Suicidality
Suicidality encompasses a spectrum of suicidal thoughts and behaviours, significantly impacting individuals globally. Recent research into psychedelics, particularly ketamine and ayahuasca, shows promise in rapidly alleviating suicidal ideation associated with mental health disorders.
What is Suicidality?
Suicidality refers to the desire to end one's own life and includes suicidal ideation, planning, and attempts. It is often associated with mental health disorders, such as depression and substance use disorders, but can also occur in individuals without any formal diagnosis.
The World Health Organization estimates over 700,000 suicide deaths each year, with individuals aged 15-19 being particularly affected. Risk factors include previous suicide attempts, mental health disorders, substance misuse, and socio-economic challenges.
Diagnosing and treating suicidality can be complex due to the range of underlying factors. Clinicians employ various assessment tools, such as the Columbia-Suicide Severity Rating Scale (C-SSRS), to evaluate risk.
Standard treatments for suicidality often involve psychotherapy and medications targeting underlying mental disorders; however, traditional antidepressants typically require weeks to yield effects, which is a critical disadvantage for those in immediate danger.
Current Treatments
Current standard-of-care treatments for suicidality include psychotherapy (e.g., cognitive behavioural therapy, dialectical behaviour therapy) and pharmacotherapy for underlying conditions, typically involving antidepressants or anxiolytics which may take weeks to become effective.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Suicidality.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Ketamine Numerous studies demonstrate ketamine's rapid efficacy in reducing suicidal ideation. | Large | High | Consistent |
| Esketamine FDA approval based on robust data showing significant improvement in depression and suicidality. | Large | High | Consistent |
| Ayahuasca While initial trials suggest potential benefits, further research is needed to establish efficacy. | Medium | Moderate | Inconsistent |
Ketamine and Suicidality
Ketamine acts as a rapid-acting antidepressant, with effects seen within hours of administration. It modulates glutamate neurotransmission, which is believed to play a role in mood regulation, potentially alleviating suicidal thoughts almost immediately due to its unique pharmacological profile.
Esketamine and Suicidality
As a nasal spray formulation of ketamine, esketamine offers a novel delivery method that allows for rapid intervention in suicidal patients. Clinical trials indicate significant decreases in suicidal ideation shortly after administration, further emphasising its role in emergency psychiatric care.
Ayahuasca and Suicidality
Ayahuasca is reported to induce intense psychological experiences which may provide therapeutic insights and emotional release for individuals struggling with suicidal thoughts. Preliminary studies suggest it could lead to significant reductions in suicidality when combined with appropriate therapeutic support.
Key Insights
- 1
Ketamine has been shown to provide rapid relief from suicidal ideation, with significant clinical improvements observed within hours of administration.
- 2
Esketamine, a derivative of ketamine, has been approved by the FDA for treatment-resistant depression and shows potential for addressing suicidality.
- 3
Recent trials indicate that ayahuasca may lead to rapid and sustained reductions in suicidal ideation among individuals with major depressive disorder.
- 4
Many existing antidepressants can exacerbate suicidal thoughts, underscoring the need for alternative treatments.
- 5
The understanding of suicidality and its treatment approaches is evolving, particularly as more research into psychedelics is conducted.
Industrial Landscape
Key players in psychedelic research for suicidality include pharmaceutical companies like Janssen Pharmaceuticals, which produces esketamine, and academic institutions such as Imperial College London, which explores the effects of psychedelics like ayahuasca.
Quick Indicators
\"Ongoing clinical evaluations are investigating Suicidality as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Suicidality.